...
首页> 外文期刊>BMC Cancer >Assessment of laparoscopic stomach preserving surgery with sentinel basin dissection versus standard gastrectomy with lymphadenectomy in early gastric cancer–A multicenter randomized phase III clinical trial (SENORITA trial) protocol
【24h】

Assessment of laparoscopic stomach preserving surgery with sentinel basin dissection versus standard gastrectomy with lymphadenectomy in early gastric cancer–A multicenter randomized phase III clinical trial (SENORITA trial) protocol

机译:早期胃癌腹腔镜胃保留手术与前哨盆腔剥离术对比标准胃切除术与淋巴结清扫术的评估–一项多中心随机III期临床试验(SENORITA试验)方案

获取原文
           

摘要

Background Along with the marked increase in early gastric cancer (EGC) in the Eastern countries, there has been an effort to adopt the sentinel node concept in EGC to preserve gastric function and reduce the occurrence of postoperative complications. Based on promising results from a previous quality control study, this prospective multicenter randomized controlled phase III clinical trial aims to elucidate the oncologic safety of laparoscopic stomach-preserving surgery with sentinel basin dissection (SBD) compared to a standard laparoscopic gastrectomy. Methods/Design This trial is an investigator-initiated, open-label, multicenter randomized controlled phase III trial with a non-inferiority design. Patients diagnosed with a single lesion of clinical stage T1N0M0 gastric adenocarcinoma, with a diameter of 3?cm or less are eligible for the present study. A total of 580 patients (290 per group) will be randomized to either laparoscopic stomach-preserving surgery with SBD or standard surgery. The primary end-point is 3-year disease-free survival (DFS) and the secondary endpoints include postoperative morbidity and mortality, quality of life, 5-year DFS, and overall survival. Qualified investigators who completed the prior quality control study are exclusively allowed to participate in this phase III clinical trial. Discussion The proposed trial is expected to verify whether laparoscopic stomach-preserving surgery with SBD achieves similar oncologic outcomes and improved quality of life compared to a standard gastrectomy in EGC patients. Trial registration This study was registered at the NIH ClinicalTrial.gov database ( NCT01804998 ) on March 4th, 2013.
机译:背景技术随着东方国家早期胃癌(EGC)的显着增加,人们一直在努力在EGC中采用前哨淋巴结概念,以保留胃功能并减少术后并发症的发生。基于之前的质量控制研究的有希望的结果,这项前瞻性多中心随机对照III期临床试验旨在阐明与标准腹腔镜胃切除术相比,腹腔镜保胃术前哨淋巴结清扫术(SBD)的肿瘤学安全性。方法/设计该试验为研究人员发起的,开放标签的多中心随机对照III期试验,采用非劣效性设计。被诊断患有直径为3?cm或更小的临床阶段T1N0M0胃腺癌的单个病变的患者符合本研究的条件。总共580位患者(每组290位患者)将被随机分配至SBD腹腔镜保胃手术或标准手术。主要终点为3年无病生存期(DFS),次要终点为术后发病率和死亡率,生活质量,5年DFS和总体生存期。已完成先前质量控制研究的合格研究人员仅可参与此III期临床试验。讨论该拟议的试验有望验证与EGC患者相比标准胃切除术,SBD腹腔镜保胃手术是否能达到类似的肿瘤学效果并改善生活质量。试验注册该研究已于2013年3月4日在NIH ClinicalTrial.gov数据库(NCT01804998)上进行了注册。

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号